CN-201 is under clinical development by Curon Biopharmaceutical and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CN-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CN-201 is under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), follicular lymphoma, marginal zone B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma and transforming large B-cell lymphoma, B-ALL. It is administered through intravenous route.
Curon Biopharmaceutical overview
Curon Biopharmaceutical is a clinical-stage innovative biopharmaceutical company focusing on immuno-oncology. It is actively involved in the development of therapies to meet unmet medical needs and offer cancer patients around the world efficient treatment options. The company has developed a pipeline of numerous inventive drug candidates through internal research and collaboration with outside parties. It utilize the unique properties of the tumor microenvironment (TME) to create molecules that can specifically target the TME while causing minimal systemic toxicity. Curon Biopharmaceutical is headquartered in Shanghai, China.
For a complete picture of CN-201’s drug-specific PTSR and LoA scores, buy the report here.